Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic.
Biological Products
/ administration & dosage
COVID-19
/ prevention & control
Colitis, Ulcerative
/ diagnosis
Crohn Disease
/ diagnosis
Cross-Sectional Studies
Delivery of Health Care, Integrated
/ organization & administration
Drug Administration Schedule
Drug Therapy, Combination
Fear
Female
Health Knowledge, Attitudes, Practice
Humans
Immunosuppressive Agents
/ administration & dosage
Infusions, Intravenous
Injections, Subcutaneous
Male
Medication Adherence
Patient Satisfaction
Time Factors
Treatment Outcome
Biologicals
COVID
Inflammatory bowel disease
Perceptions
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
22
11
2020
accepted:
22
12
2020
pubmed:
21
1
2021
medline:
20
11
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
The outbreak of COVID19 evolved rapidly into a global pandemic, forcing hospitals, including inflammatory bowel disease (IBD) referral units, to change their practices to ensure quality of care. To describe the clinical outcomes and the fulfilment of the treatment schedule of patients with IBD treated with biological agents in a single-center of a red-zone of the pandemic, and to report the patients' perceptions about COVID-19 and the measures adopted at our center. Therapeutic adherence and clinical outcomes were collected for all patients undergoing treatment with intravenous biologicals and subcutaneous biologicals at our center. A telephone survey was also performed to assess these patients' perceptions of the COVID pandemic and the related measures adopted at their IBD unit. A total of 234 patients were included (117 on intravenous and 117 on subcutaneous biologicals). Only 10% of patients postponed intravenous infusions intentionally and 5% postponed the collection of subcutaneous biologicals at the hospital pharmacy. Only five confirmed COVID-19 cases were registered (2.1%), all of them of mild severity. One hundred and fifty-five patients participated in the survey (77 on intravenous and 78 on subcutaneous drugs). Fear of going to the hospital was the most common reason for postponing biological administrations. Among those on combination therapy, only 7% admitted to have withdrawn immunosuppressants. Adherence to intravenous and subcutaneous biological therapies during the pandemic was high in a single-center cohort of IBD patients even though the cumulative incidence of confirmed COVID-19 was low.
Sections du résumé
BACKGROUND
The outbreak of COVID19 evolved rapidly into a global pandemic, forcing hospitals, including inflammatory bowel disease (IBD) referral units, to change their practices to ensure quality of care.
AIMS
To describe the clinical outcomes and the fulfilment of the treatment schedule of patients with IBD treated with biological agents in a single-center of a red-zone of the pandemic, and to report the patients' perceptions about COVID-19 and the measures adopted at our center.
METHODS
Therapeutic adherence and clinical outcomes were collected for all patients undergoing treatment with intravenous biologicals and subcutaneous biologicals at our center. A telephone survey was also performed to assess these patients' perceptions of the COVID pandemic and the related measures adopted at their IBD unit.
RESULTS
A total of 234 patients were included (117 on intravenous and 117 on subcutaneous biologicals). Only 10% of patients postponed intravenous infusions intentionally and 5% postponed the collection of subcutaneous biologicals at the hospital pharmacy. Only five confirmed COVID-19 cases were registered (2.1%), all of them of mild severity. One hundred and fifty-five patients participated in the survey (77 on intravenous and 78 on subcutaneous drugs). Fear of going to the hospital was the most common reason for postponing biological administrations. Among those on combination therapy, only 7% admitted to have withdrawn immunosuppressants.
CONCLUSIONS
Adherence to intravenous and subcutaneous biological therapies during the pandemic was high in a single-center cohort of IBD patients even though the cumulative incidence of confirmed COVID-19 was low.
Identifiants
pubmed: 33469807
doi: 10.1007/s10620-020-06807-0
pii: 10.1007/s10620-020-06807-0
pmc: PMC7814978
doi:
Substances chimiques
Biological Products
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4191-4196Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Martin Arranz E, Suarez Ferrer C, García Ramírez L, et al. Management of COVID-19 pandemic in Spanish inflammatory bowel disease units: results from a national survey. Inflamm Bowel Dis. 2020;26:1149–1154.
pubmed: 32495826
Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020;52:54–72.
doi: 10.1111/apt.15779
Zhou H, Fang Y, Xu T, Ni WJ, Shen AZ, Meng XM. Potential therapeutic targets and promising drugs for combating SARS-CoV-2. Br J Pharmacol. 2020;177:3147–3161.
doi: 10.1111/bph.15092
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481.e1–491.e3.
doi: 10.1053/j.gastro.2020.05.032
Brenner EJ, Ungaro RC, Colombel JF, et al. SECURE-IBD Database public data update. https://covidibd.org/current-data/ . Accessed August 30, 2020.
Zabana Y, Panés J, Nos P, et al. The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions. Gastroenterol Hepatol. 2020;43:551–558.
doi: 10.1016/j.gastrohep.2020.05.007
Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276–283.
doi: 10.1111/apt.15804
Guerra I, Algaba A, Jiménez L, et al. Incidence, clinical characteristics, and evolution of SARS-Cov-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain. Inflamm Bowel Dis. 2020. https://doi.org/10.1093/ibd/izaa221 .
doi: 10.1093/ibd/izaa221
Hanzel J, Ma C, Marshall JK, Feagan BG, Jairath V. Managing inflammatory bowel disease during COVID-19: summary of recommendations from gastrointestinal societies. Clin Gastroenterol Hepatol. 2020;18:2143–2146.
doi: 10.1016/j.cgh.2020.04.033
D’Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, Danese S. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. Lancet Gastroenterol Hepatol. 2020;5:631–632.
doi: 10.1016/S2468-1253(20)30151-5
Grunert PC, Reuken PA, Stallhofer J, Teich N, Stallmach A. Inflammatory bowel disease in the COVID-19 pandemic—the patients’ perspective. J Crohns Colitis. 2020. https://doi.org/10.1093/ecco-jcc/jjaa126 .
doi: 10.1093/ecco-jcc/jjaa126
pubmed: 32564068
Scaldaferri F, Pugliese D, Privitera G, et al. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre. United Eur Gastroenterol J. 2020;8:775–781.
doi: 10.1177/2050640620929133